Iqvia today launched a new “patient centered endpoints” solution, which captures the patient experience during clinical trials and real world studies, says SVP.
CRF Bracket – newly-rebranded as Signant Health – is looking to build momentum around eConsent, rethink the patient’s connection to the supply chain, and build out a stronger analytics platform, says CEO.
Analytical software provider and CRO, Cytel, and biostatistics company, Axio Research, merge to deliver analytical solutions for clinical research drug development challenges.
Females as caregivers, clinical trial participants, and biopharma leaders are among the different roles to be carefully considered as the industry aims for increased inclusion, says BBK executive.
New this year to the discussion at DIA is the conversation around data ownership, as the industry continues to face a deluge of information from more sources than ever.
Parexel forms a strategic partnership with Clariness to deploy the ClinLife platform in the Greater China area as the CRO looks to recruit and engage patients in their native language and via social media channels.
Translational research faces new challenges – and opportunities – with the rapid growth in precision medicine and new drug modalities, as the industry looks to quickly bring new treatments to patients.
Clinical research in England is growing at a record-setting pace with support from a recent £20.5bn investment to transform service delivery – as the NHS looks to conduct more studies in primary care settings.
Verily is aligning itself with big names in pharma to bolster its Project Baseline, designed to use digital sources to promote patient-centered clinical research programs.
Social, cultural, and financial barriers pose a challenge in enrollment for oncology clinical trials, but USC investigator believes mitigating barriers to diversify research may provide comprehensive data.
Kazia therapeutics is collaborating with the Alliance for Clinical Trials in Oncology Foundation to launch a Phase II study to investigate its brain cancer therapies targeted at tumors’ genetic profile.
